High Rates of Venous Thromboembolism Prophylaxis Did Not Increase the Incidence of Heparin-Induced Thrombocytopenia
Abstract:Background: Venous thromboembolism (VTE) prophylaxis is recommended for most hospitalized patients. At a 505-bed urban academic medical center, the rate of VTE prophylaxis recently increased from 50%–55% to > 95% of eligible patients. Heparin-induced thrombocytopenia (HIT) is a potentially devastating, but rare, reaction to medications commonly used for VTE prophylaxis.
Methods: Patients were identified who were tested for HIT, treated with direct thrombin inhibitors (DTIs), or received International Classification of Diseases, 9th Revision codes consistent with HIT ("suspected HIT") from January 2005 through April 2008. Two physicians classified each patient as having confirmed, possible, or excluded HIT on the basis of laboratory testing, final diagnosis, and clinical course. The rate of suspected and confirmed HIT during the latter two years was compared to rates during the first (reference) year of the project.
Results: Some 430 unique patients had received HIT testing or DTI therapy for possible HIT. Thirteen cases of confirmed HIT were identified, of which 7 were due to treatment at the institution and 2 occurred while on VTE prophylaxis. HIT was confirmed in 0.02% of hospital admissions and only 3% of patients initially tested or treated for HIT. Rates of suspected and confirmed HIT did not change during the study period (Risk Ratios [95% confidence intervals] 0.976 [0.77–1.23] and 1.09 [0.39–2.99]).
Conclusions: Optimizing the VTE prophylaxis rate to > 95% of eligible patients at a single academic institution did not cause an increase in the rate of HIT. Concerns about HIT should not limit implementation of VTE prophylaxis protocols. HIT surveillance in patients on VTE prophylaxis may have a very low yield.
Document Type: Research Article
Publication date: 2011-04-01
More about this publication?
- The Joint Commission Journal on Quality and Patient Safety will be published by Elsevier beginning in 2017! For readers who receive access to the journal through their institutions, the journal can now be found on ScienceDirect (http://www.sciencedirect.com/science/journal/15537250). For librarians looking to subscribe to the journal for their institutions please contact your Elsevier Account Manager or visit www.myelsevier.com for more information. All other readers, please visit http://www.jointcommissionjournal.com/ to subscribe to the journal or to claim your access for an existing subscription.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Information for Advertisers
- Reprints and Permissions
- Ingenta Connect is not responsible for the content or availability of external websites